4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-126410
Chief Development Officer sold 10,115 shares at $29.99 ($303,355)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-03-25 | Sale 10b5-1 | −10,115 | $29.99 | $303,355 | 286,876 | D: show line 1 in the form |
| Open-market sales · 10,115 sh · avg $29.99 · $303,355 | |||||||
Loading xslF345X06/ownership.xml…